DiaGenic fourth quarter operating revenue increases to NOK 1,078 thousand
 

DiaGenic has significantly altered its business strategy during 2010 to leverage more effectively its commercial potential, and strengths in Intellectual Property (IP). The Company has made significant progress in its business activities towards big pharma since implementation of the new strategy. DiaGenic is well positioned as a multimodal partner with large pharma and imaging companies.

More...